Abstract
A single-arm, open-label, multi-cohort, multi-center phase II clinical study of anlotinib combined with penpulimab in the treatment of recurrent or metastatic gynecological cancer: ALTER-GO-020 (1244)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have